Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores

Bibliographic Details
Main Authors:	Xavier Adhoute, Thomas Wolf
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2022-12-01
Series:	Hepatology Communications
Online Access:	https://doi.org/10.1002/hep4.2047

Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma
by: Xiaomi Li, et al.
Published: (2022-12-01)

Angiogenesis in hepatocellular carcinoma: mechanisms and anti-angiogenic therapies
by: Changyu Yao, et al.
Published: (2023-01-01)

bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti‐angiogenic agent apatinib combination therapy
by: Gehan Xu, et al.
Published: (2022-10-01)

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study
by: Ke Su, et al.
Published: (2022-09-01)

Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
by: Liang H, et al.
Published: (2019-08-01)

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma
by: Hideko Ohama, et al.
Published: (2024-04-01)

Nivolumab plus Ipilimumab: A Novel First-Line Combination Immunotherapy for Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2024-08-01)

Adjuvant Transarterial Chemoembolization Plus Immunotherapy for Huge Hepatocellular Carcinoma: A Propensity Score Matching Cohort Study
by: Huang H, et al.
Published: (2024-04-01)

Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
by: Ruben S. A. Goedegebuure, et al.
Published: (2019-01-01)

The Potential Predictive Biomarkers for Advanced Hepatocellular Carcinoma Treated With Anti-Angiogenic Drugs in Combination With PD-1 Antibody
by: Chenxi Liu, et al.
Published: (2022-07-01)

Prognostic significance of the CRAFITY score in hepatocellular carcinoma treated with immunotherapy: a systematic review and meta-analysis
by: Ming Yang, et al.
Published: (2023-03-01)

Combination of Anti-Angiogenics and Immunotherapies in Renal Cell Carcinoma Show Their Limits: Targeting Fibrosis to Break through the Glass Ceiling?
by: Manon Teisseire, et al.
Published: (2024-02-01)

The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer
by: Brigida Anna Maiorano, et al.
Published: (2022-10-01)

The AFCRPLITY score for predicting the prognosis of immunotherapy combined with local–regional therapy in unresectable hepatocellular carcinoma
by: Mengxuan Zuo, et al.
Published: (2024-11-01)

Anti-angiogenic and anti-hepatocellular carcinoma properties of zerumbone extracted from Zingiber Zerumbet (l.) Smith
by: Abdul Samad, Nozlena
Published: (2015)

Prognostic impact of body composition in hepatocellular carcinoma patients with immunotherapy
by: Lilong Zhang, et al.
Published: (2024-12-01)

Comparative Efficacy of Lenvatinib Plus Immunotherapy and Regorafenib Plus Immunotherapy After Lenvatinib Failure for Advanced Hepatocellular Carcinoma: A Retrospective Study
by: Zeyu Yu, et al.
Published: (2025-01-01)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
by: De-Zhen Guo, et al.
Published: (2023-02-01)

Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report Study
by: Zheng Yan, et al.
Published: (2021-11-01)

Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengzhou Zhu, et al.
Published: (2024-09-01)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
by: Liting Zhong, et al.
Published: (2021-05-01)

Long-term disease-free survival achieved by anti-angiogenic therapy plus surgery in a hepatocellular carcinoma patient with extensive liver involvement and lung metastases
by: Yu-Yun Shao, et al.
Published: (2014-08-01)

The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma
by: Kinoshita Akiyoshi, et al.
Published: (2013-02-01)

Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy
by: Yang H, et al.
Published: (2024-01-01)

Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab
by: Chiun Hsu, et al.
Published: (2021-07-01)

Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
by: Shuqun Li, et al.
Published: (2023-02-01)

Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma
by: Jiajing Zhao, et al.
Published: (2023-12-01)

Immunotherapy for hepatocellular carcinoma
by: Xiaoxia Wang, et al.
Published: (2024-08-01)

Immunotherapy in hepatocellular carcinoma
by: Luigi Buonaguro, et al.
Published: (2019-03-01)

First-line combination therapy of immunotherapy plus anti-angiogenic drug for thoracic SMARCA4-deficient undifferentiated tumors in AIDS: a case report and review of the literature
by: Xiaoling Wei, et al.
Published: (2025-01-01)

Combination Immunotherapy with Anti-PD-1/PD-L1 Antibody plus Anti-VEGF Antibody May Promote Cytotoxic T Lymphocyte Infiltration in Hepatocellular Carcinoma, Including in the Noninflamed Subclass
by: Masatoshi Kudo
Published: (2022-05-01)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
by: Jian Qin, et al.
Published: (2022-04-01)

Depth of radiographic response as an independent prognostic factor for patients with initially unresectable hepatocellular carcinoma receiving hepatectomy following targeted therapy plus immunotherapy
by: Bin Xu, et al.
Published: (2024-09-01)

Corrigendum: Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
by: Shuqun Li, et al.
Published: (2023-04-01)

Prognostic Effect of Sarcopenia in Hepatocellular Carcinoma Patients Targeted with Interventional Therapy Combined with Immunotherapy and Targeted Therapy [Corrigendum]
by: Yang H, et al.
Published: (2024-03-01)

Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma
by: Zehao Zheng, et al.
Published: (2025-01-01)

Erratum to “Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab”
Published: (2021-09-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01)

Anti‐angiogenic therapy enhances cancer immunotherapy: Mechanism and clinical application
by: An‐Qi Li, et al.
Published: (2024-01-01)

Extracellular vimentin mimics VEGF and is a target for anti-angiogenic immunotherapy
by: Judy R. van Beijnum, et al.
Published: (2022-05-01)

Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores

Similar Items

Similar Items